Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26381747 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL13301154 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL997382 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL15890590 | 0.98 | TSHR (0.46) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL19999151 | 0.91 | CYP2C19 (0.46) | MEN1KMT2ATSHRCYP2C19POLB | |
| SCHEMBL17883360 | 0.91 | CYP2C19 (0.46) | MEN1KMT2ATSHRCYP2C19POLB | |
| SCHEMBL1777653 | 0.89 | CYP2C19 (0.48) | TSHRCYP2C19POLBBLMATM | |
| SCHEMBL1469721 | 0.84 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL29518865 | 0.84 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL30372269 | 0.84 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241429-A1 | Antifolate-Carrying Nanoparticles and Their Use in Medicine | MIDATECH LTD (GB) | 2022-08-04 | — | — | US | disclosed |
| US-20220047718-A1 | Nanoparticle-Based Therapy of Inflammatory Disorders | MIDATECH LTD (GB) | 2022-02-17 | — | — | US | disclosed |
| EP-3893939-A1 | NANOPARTICLE-BASED THERAPY OF INFLAMMATORY DISORDERS | Midatech Ltd (GB) | 2021-10-20 | — | — | EP | disclosed |
| EP-3893938-A1 | ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE | Midatech Ltd (GB) | 2021-10-20 | — | — | EP | disclosed |
| CN-113423433-A | Nanoparticles carrying antifolates and their use in medicine | MIDA科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-113412126-A | Nanoparticle-based therapy for inflammatory disorders | MIDA科技有限公司 | 2021-09-17 | — | — | CN | disclosed |
| US-10688125-B2 | Nanoparticles and their use in cancer therapy | MIDATECH LTD. (GB) | 2020-06-23 | — | — | US | disclosed |
| WO-2020120787-A1 | NANOPARTICLE-BASED THERAPY OF INFLAMMATORY DISORDERS | MIDATECH LTD (GB) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120785-A1 | ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE | MIDATECH LTD (GB) | 2020-06-18 | — | — | WO | disclosed |
| EP-3217958-B1 | SUSTAINED RELEASE ENCAPSULATED NANOPARTICLES | MIDATECH LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-8568781-B2 | Peptide-carrying nanoparticles | MIDATECH LIMITED (GB) | 2013-10-29 | — | — | US | disclosed |
| EP-2579898-A1 | PEPTIDE-CARRYING NANOPARTICLES | Midatech Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| EP-2579844-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | Schobel, Alexander M. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012170828-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | MONOSOL RX, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH PHARMA PLC (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH PHARMA PLC (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | AQUESTIVE THERAPEUTICS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | AQUESTIVE THERAPEUTICS, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688125-B2 | Nanoparticles and their use in cancer therapy | EPCAM, CLTA, CORO1A | MEN1 2759/4885KMT2A 1084/4885TSHR 1865/4885 |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | CALCA, LNPEP, CLTA | MEN1 1777/4885KMT2A 2914/4885TSHR 1406/4885 |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | CD63, DSTN, EPCAM | MEN1 1868/4885KMT2A 3018/4885TSHR 2655/4885 |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | CALCA, LNPEP, IAPP | MEN1 1383/4885KMT2A 3874/4885TSHR 757/4885 |
| US-20220047718-A1 | Nanoparticle-Based Therapy of Inflammatory Disorders | MTX1, LANCL1, CD44 | MEN1 2325/4885KMT2A 2964/4885TSHR 3244/4885 |
| US-20220241429-A1 | Antifolate-Carrying Nanoparticles and Their Use in Medicine | FOLR1, FOLR2, SLC19A1 | MEN1 1052/4885KMT2A 2988/4885TSHR 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.